Dual time point 18F-FDG PET imaging detects breast cancer with high sensitivity and correlates well with histologic subtypes.

UNLABELLED This prospective study was designed to assess the utility of the dual time point imaging technique by (18)F-FDG PET in detecting primary breast cancer and to determine whether there is a relationship between (18)F-FDG uptake and its change over time and the histopathologic subtypes. METHODS One hundred fifty-two patients with newly diagnosed breast cancer underwent 2 sequential PET scans (dual time point imaging) for preoperative staging. The maximum standardized uptake value (SUVmax) of (18)F-FDG was measured from both time points. The percent change in SUVmax (Delta%SUVmax) between time points 1 (SUVmax1) and 2 (SUVmax2) was calculated. Patients were divided into 2 groups according to histopathology as invasive and noninvasive. Invasive tumors were also divided into 2 groups (>10 mm and 4-10 mm). The tumor-to-contralateral normal breast (background) ratios of SUVmax at both time points for groups were measured and the Delta%SUVmax values were calculated. RESULTS The mean +/- SD of the SUVmax1, the SUVmax2, and the Delta%SUVmax were 3.9 +/- 3.7, 4.3 +/- 4.0, and 8.3% +/- 11.5% for invasive; 2.0 +/- 0.6, 2.1 +/- 0.6, and 3.4% +/- 13.0% for noninvasive; and were 1.2 +/- 0.3, 1.1 +/- 0.2, and -10.0% +/- 10.8% for the contralateral normal breast groups, respectively. In the comparison of SUVmax1, Delta%SUVmax, and the tumor-to-background ratios among groups, all results were significant (P < 0.001). Visual assessment revealed that the sensitivity of dual time point imaging was 90.1% for invasive cancer >10 mm, 82.7% for invasive breast cancers 4-10 mm, and 76.9% for noninvasive breast cancers. CONCLUSION Dual time point imaging is a simple and noninvasive method that may improve the sensitivity and accuracy of (18)F-FDG PET in assessing patients with primary breast cancer. The changes that are noted in SUVs in dual time point imaging vary depending on the histopathologic type of primary breast cancer.

[1]  M. Schwaiger,et al.  Breast imaging with positron emission tomography and fluorine-18 fluorodeoxyglucose: use and limitations. , 2000, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[2]  R L Wahl,et al.  An Immunohistochemical Study , 2006 .

[3]  N. Dubrawsky.  Cancer statistics , 1989, CA: a cancer journal for clinicians.

[4]  H. Herzog,et al.  Optimal scan time for fluorine-18 fluorodeoxyglucose positron emission tomography in breast cancer , 1999, European Journal of Nuclear Medicine.

[5]  A. Jemal,et al.  Cancer Statistics, 2005 , 2005, CA: a cancer journal for clinicians.

[6]  A. Alavi,et al.  Dual time point fluorine-18 fluorodeoxyglucose positron emission tomography: a potential method to differentiate malignancy from inflammation and normal tissue in the head and neck , 1999, European Journal of Nuclear Medicine.

[7]  K. Scheidhauer,et al.  FDG PET and other imaging modalities in the primary diagnosis of suspicious breast lesions , 2004, European Journal of Nuclear Medicine and Molecular Imaging.

[8]  H. Sakahara,et al.  Delayed 18F‐fluoro‐2‐deoxy‐D‐glucose positron emission tomography scan for differentiation between malignant and benign lesions in the pancreas , 2000, Cancer.

[9]  A. Alavi,et al.  Dual time point 18F-FDG PET imaging for differentiating malignant from inflammatory processes. , 2001, Journal of nuclear medicine : official publication, Society of Nuclear Medicine.

[10]  L M Hamberg,et al.  The dose uptake ratio as an index of glucose metabolism: useful parameter or oversimplification? , 1994, Journal of nuclear medicine : official publication, Society of Nuclear Medicine.

[11]  Paul Kinahan,et al.  SUV varies with time after injection in (18)F-FDG PET of breast cancer: characterization and method to adjust for time differences. , 2003, Journal of nuclear medicine : official publication, Society of Nuclear Medicine.

[12]  Yoshiharu Yonekura,et al.  18F-FDG accumulation with PET for differentiation between benign and malignant lesions in the thorax. , 2003, Journal of nuclear medicine : official publication, Society of Nuclear Medicine.

[13]  Shih-Ya Ma,et al.  Delayed 18F-FDG PET for Detection of Paraaortic Lymph Node Metastases in Cervical Cancer Patients , 2003 .

[14]  M. Younes,et al.  Wide expression of the human erythrocyte glucose transporter Glut1 in human cancers. , 1996, Cancer research.

[15]  R L Wahl,et al.  Primary and metastatic breast carcinoma: initial clinical evaluation with PET with the radiolabeled glucose analogue 2-[F-18]-fluoro-2-deoxy-D-glucose. , 1991, Radiology.

[16]  U. Pietrzyk,et al.  Qualitative [18F]FDG positron emission tomography in primary breast cancer: clinical relevance and practicability , 1996, European Journal of Nuclear Medicine.

[17]  Michael E. Phelps,et al.  Cancer Detection with Whole‐Body PET Using 2‐[18F]Fluoro‐2-Deoxy‐D-Glucose , 1993, Journal of computer assisted tomography.

[18]  N. Tallada,et al.  An Immunohistochemical Study , 1992 .

[19]  A. Alavi,et al.  Fluorodeoxyglucose-PET in characterizing solitary pulmonary nodules, assessing pleural diseases, and the initial staging, restaging, therapy planning, and monitoring response of lung cancer. , 2005, Radiologic clinics of North America.

[20]  Thomas Beyer,et al.  Advantages and limitations of FDG PET in the follow-up of breast cancer , 2004, European Journal of Nuclear Medicine and Molecular Imaging.

[21]  P. Marsden,et al.  A PET study of 18FDG uptake in soft tissue masses , 1999, European Journal of Nuclear Medicine.

[22]  H. Schirrmeister,et al.  Fluorine-18 2-deoxy-2-fluoro-D-glucose PET in the preoperative staging of breast cancer: comparison with the standard staging procedures , 2001, European Journal of Nuclear Medicine.

[23]  David A Mankoff,et al.  Evolving role of positron emission tomography in breast cancer imaging. , 2005, Seminars in nuclear medicine.

[24]  J S Karp,et al.  Whole-body positron emission tomography for oncology imaging using singles transmission scanning with segmentation and ordered subsets-expectation maximization (OS-EM) reconstruction. , 1998, European journal of nuclear medicine.

[25]  M Schwaiger,et al.  Metabolic characterization of breast tumors with positron emission tomography using F-18 fluorodeoxyglucose. , 1996, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[26]  J L Sunshine,et al.  Evaluation of breast masses and axillary lymph nodes with [F-18] 2-deoxy-2-fluoro-D-glucose PET. , 1993, Radiology.

[27]  Abass Alavi,et al.  Dual time point 18F-FDG PET for the evaluation of pulmonary nodules. , 2002, Journal of nuclear medicine : official publication, Society of Nuclear Medicine.

[28]  N. Avril,et al.  Positron emission tomography for the diagnosis of breast cancer , 2002, Nuclear medicine communications.